Valvular & structural heart disease

Long-Term Outcomes of Patients Requiring Pacemaker Implantation After Transcatheter Aortic Valve Replacement: The SwissTAVI Registry

JACC Cardiovasc IntervPublished Prospective cohort study

Authors' conclusion

In this large nationwide registry, patients receiving PM implantation within 30 days after TAVR had significantly higher rates of overall and cardiovascular mortality up to 10 years.

Study context

Population
Patients undergoing transcatheter aortic valve replacement (TAVR) at 19 centres across Switzerland, February 2011 to June 2022 (SwissTAVI Registry)
Participants
13,360 patients
Exposure
Pacemaker (PM) implantation within 30 days post-TAVR vs no PM
  • PMn = 2,028
Outcome
All-cause and CV mortality
Follow-up
1 year
Methodological detailsobservational, nationwide, multicentre (19 centres)
  • Observational
  • Nationwide
  • Multicentre (19 centres)

Main finding

As reported in the abstract

Mortality
PM vs No PMAdjusted hazard ratio (95% CI)P value
All-cause mortality
1.15(1.05–1.26)
P = 0.002
CV mortality
1.25(1.06–1.46)
P = 0.006

Observational data: associations, not effects.

Further findings

OutcomeaHR (95% CI)P value
CV mortality, LVEF decline ≥10%, NYHA class III or IV · 1 year · after multivariable adjustment1.44 (1.35–1.54)P < 0.001

All-cause and CV mortality · 5 and 10 years

Higher all-cause and CV mortality with PM at 5- and 10-year follow-up

Original publication

Long-Term Outcomes of Patients Requiring Pacemaker Implantation After Transcatheter Aortic Valve Replacement: The SwissTAVI Registry. JACC Cardiovasc Interv. Published 1 April 2025. doi:10.1016/j.jcin.2025.03.028

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.